Business Context and Reporting Period
Company: Drugs Made In America Acquisition II Corp. (DMII)
Reporting Period: Quarter ended September 30, 2025 (Nine months from inception on August 23, 2024).
Business Overview: DMII is a Cayman Islands blank check company (SPAC) formed to effect a business combination with a target in the pharmaceutical industry. The company consummated its Initial Public Offering (IPO) on September 26, 2025. As of the reporting date, the company has not commenced operations and has not selected a business combination target.
Key Financial Metrics
| Metric | Value (as of Sept 30, 2025) |
|---|---|
| Trust Account Balance | $500,109,355 |
| Cash (Outside Trust) | $315,087 |
| Total Assets | $501,005,711 |
| Total Liabilities | $18,177,345 |
| Deferred Underwriting Fee | $17,500,000 |
| Net Loss (3 Months Ended Sept 30, 2025) | $(46,158) |
| Net Loss (9 Months Ended Sept 30, 2025) | $(143,558) |
| Operating Expenses (G&A) | $252,913 (9 Months) |
| Interest Income (Trust Account) | $109,355 (9 Months) |
| Shares Outstanding (Public) | 50,000,000 (Subject to redemption) |
| Shares Outstanding (Founder/Private) | 15,575,000 |
Material Changes vs. Prior Period
- Capitalization Event: The most significant change is the consummation of the IPO on September 26, 2025. The company raised $500,000,000 from the sale of 50,000,000 Units and $12,000,000 from the sale of 1,200,000 Private Placement Units.
- Trust Account: The Trust Account balance increased from $0 to $500,109,355, funded by IPO proceeds and initial interest earnings.
- Liabilities: Total liabilities increased from $254,783 (Dec 31, 2024) to $18,177,345, primarily driven by the recognition of a $17,500,000 deferred underwriting fee and a $553,748 over-allotment liability.
- Shareholder Deficit: Shareholders' deficit increased significantly to $(17,280,989) due to the accretion of redeemable shares to their redemption value and the allocation of offering costs.
- Related Party Transactions: The company repaid a $325,000 promissory note to the Sponsor. A receivable of $566,269 is now due from the Sponsor due to an overpayment.
Outlook, Risks, and Management Commentary
- Combination Period: The company has 24 months from the IPO closing (September 26, 2025) to complete a business combination. If unsuccessful, the company will liquidate and redeem public shares.
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year due to the mandatory liquidation date and the requirement to complete a business combination to survive.
- Liquidity: Working capital outside the Trust Account is $219,011. The company relies on the Trust Account for the business combination and may require additional working capital loans from the Sponsor or affiliates to fund operations prior to the combination.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, citing material weaknesses including inadequate segregation of duties and insufficient written policies.
- Risks: Key risks include the inability to complete a business combination, geopolitical instability (Russia-Ukraine, Israel-Hamas conflicts) affecting capital markets, and cybersecurity threats given reliance on third-party digital infrastructure.
Investor Verification Checklist
- Trust Account Composition: Verify that the $500M+ in the Trust Account is invested solely in U.S. government treasury obligations or money market funds as required.
- Deferred Underwriting Fee: Confirm the $17,500,000 deferred fee is contingent solely on the completion of a business combination.
- Over-Allotment Option: Monitor the status of the 45-day over-allotment option for 7,500,000 additional units, which remains unexercised as of the filing date.
- Internal Control Remediation: Review future filings for plans to remediate the material weaknesses in internal controls over financial reporting.
- Related Party Receivables: Track the collection of the $566,269 due from the Sponsor to ensure it does not impact working capital.